Sanath K Meegalla

This inventor holds 42 USPTO granted patents and 2 published patent applications, plus 7 CIPO patents and 11 EPO patents, primarily in Diabetes Treatment. Top assignees: Janssen Pharmaceutica Nv, 3-Dimensional Pharmaceuticals, Inc., Bristol-Myers Squibb Compnay. Active years: 2002-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sanath K Meegalla. Retrieved from https://idiyas.com/inventor/sanath-k-meegalla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 42 (Patent Applications = 2)

% Patents Active = 45.2

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 7)

Average Co-Inventor Count = 6.4

ph-index = 9

Forward Citations = 203(Granted Patents)

Location History:

Devon, PA (US) (2002 - 2003)
Boothwyn, PA (US) (2006 - 2014)
Garnet, NJ (US) (2015 - 2016)
Garnet Valley, PA (US) (2014 - 2021)

Company Filing History:

35 out of 2,101

Janssen Pharmaceutica Nv

patents

4 out of 77

3-Dimensional Pharmaceuticals, Inc.

patents

1 out of 3,745

Bristol-Myers Squibb Compnay

patents

4. 2 out of 834,570

Other

patents

Years Active: 2002-2021

Loading Chart...

Areas of Expertise:

GPR40 Agonists

Type II Diabetes

PDE10a Inhibitors

TRPM8 Receptor Modulators

C-KIT Kinase

c-fms Kinase

Aza-Bicyclic Imidazole

Benzothiophenyl Derivatives

Heterocyclic Benzimidazoles

Arylamide Compounds

Quinolinone Derivatives

Proliferative Disorders

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10988433 - Cyclohexyl GPR40 agonists for the treatment of type II diabetes (2021-04-27),

2. 10106553 - Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes (2018-10-23),

3. 9920040 - GPR40 agonists for the treatment of type II diabetes (2018-03-20),

4. 9908873 - GPR40 agonists for the treatment of type II diabetes (2018-03-06),

5. 9856245 - GPR40 agonists for the treatment of type II diabetes (2018-01-02),

6. 9718820 - Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators (2017-08-01),

7. 9688642 - Substituted pyrazines as GPR40 agonists (2017-06-27),

8. 9526731 - Method of inhibiting C-KIT kinase (2016-12-27),

9. 9452996 - Inhibitors of c-fms kinase (2016-09-27),

10. 9409915 - Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators (2016-08-09),

11. 9403804 - Inhibitors of c-fms kinase (2016-08-02),

12. 9394289 - Inhibitors of c-fms kinase (2016-07-19),

13. 9296726 - Inhibitors of c-fms kinase (2016-03-29),

14. 9249163 - PDE10a inhibitors for the treatment of type II diabetes (2016-02-02),

15. 9221797 - Inhibitors of c-fms kinase (2015-12-29),

Title: Sanath K Meegalla: Innovator in Diabetes Treatment Technologies

Introduction: Sanath K Meegalla is an accomplished inventor based in Boothwyn, Pennsylvania, with a remarkable portfolio of 42 patents. His work focuses on innovative compounds and methods aimed at treating type II diabetes, particularly through the modulation of the GPR40 receptor.

Latest Patents: Among his latest innovations, Meegalla has developed cyclohexyl GPR40 agonists designed for the treatment of type II diabetes. These compounds and compositions offer a new approach to managing disorders influenced by GPR40 receptor modulation. Additionally, he has introduced substituted benzothiophenyl derivatives as GPR40 agonists for similar therapeutic applications, further expanding the possibilities for diabetes treatment. Each of these compounds is characterized by specific structural formulas that showcase their potential efficacy.

Career Highlights: Over the years, Sanath K Meegalla has made significant contributions while working with reputable organizations such as Janssen Pharmaceutica and 3-Dimensional Pharmaceuticals, Inc. His experience in these companies has equipped him with the expertise needed to innovate in the pharmaceutical field.

Collaborations: Throughout his career, Meegalla has collaborated with talented individuals like Jinsheng Chen and Carl R. Illig. These partnerships underline the importance of teamwork in driving advancements in biomedical research and patentable inventions.

Conclusion: Sanath K Meegalla’s innovative work in the development of compounds for the treatment of type II diabetes exemplifies his dedication to advancing medical science. His extensive patent portfolio not only highlights his achievements but also signifies his ongoing commitment to finding effective treatments for chronic health conditions.

Profile summary based on public USPTO records.